A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

About the trial

Sponsor

AbbVie

Tested

ABBV-711 (drug), Budigalimab (drug)

Dates

Started 2025-11-20; completion 2030-10

Results posted

Not yet

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors. ABBV-711 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-711 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 220 adult participants will be enrolled in the study across 40 sites worldwide. In pa…

From ClinicalTrials.gov, last updated 2026-08-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $1,498 in research payments for this study in 2025 (3 payments).

Products named: Linzess

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.